INTRODUCTION: This study aimed at defining protease (PR) resistance mutations associated with darunavir (DRV) failure and PR resistance evolution at DRV failure in a large database of treatment-experienced human immunodeficiency virus (HIV) patients. RESULTS: Overall, 1,104 patients were included: 118 (10.7%) failed at a median observation time of 16 months. The mean number of PR mutations at baseline was 2.7, but it was higher in patients who subsequently failed DRV. In addition, the number of PR mutations increased at failure. The increase in the mean number of mutations was completely related to mutations considered to be associated with DRV resistance following the indications of the main DRV clinical trials. DISCUSSION: The higher statistical difference at baseline between failing versus non-failing patients was observed for the V32I and I84V mutations. At DRV failure, the major increase was still observed for V32I; I54L, V11I, T74P and I50V also increased. Despite the increment in the mean number of mutations per patient between baseline and failure, in 21 patients (17.8%) at baseline and 36 (30.5%) at failure, no PR mutation was detected. CONCLUSION: The HIV-DB interpretation algorithm identified few patients with full DRV resistance at baseline and few patients developed full resistance at DRV failure, indicating that complete resistance to DRV is uncommon.
INTRODUCTION: This study aimed at defining protease (PR) resistance mutations associated with darunavir (DRV) failure and PR resistance evolution at DRV failure in a large database of treatment-experienced human immunodeficiency virus (HIV) patients. RESULTS: Overall, 1,104 patients were included: 118 (10.7%) failed at a median observation time of 16 months. The mean number of PR mutations at baseline was 2.7, but it was higher in patients who subsequently failed DRV. In addition, the number of PR mutations increased at failure. The increase in the mean number of mutations was completely related to mutations considered to be associated with DRV resistance following the indications of the main DRV clinical trials. DISCUSSION: The higher statistical difference at baseline between failing versus non-failing patients was observed for the V32I and I84V mutations. At DRV failure, the major increase was still observed for V32I; I54L, V11I, T74P and I50V also increased. Despite the increment in the mean number of mutations per patient between baseline and failure, in 21 patients (17.8%) at baseline and 36 (30.5%) at failure, no PR mutation was detected. CONCLUSION: The HIV-DB interpretation algorithm identified few patients with full DRV resistance at baseline and few patients developed full resistance at DRV failure, indicating that complete resistance to DRV is uncommon.
Authors: Françoise Brun-Vézinet; Dominique Costagliola; Mounir Ait Khaled; Vincent Calvez; François Clavel; Bonaventura Clotet; Richard Haubrich; Dale Kempf; Marty King; Daniel Kuritzkes; Randall Lanier; Michael Miller; Veronica Miller; Andrews Phillips; Deenan Pillay; Jonathan Schapiro; Janna Scott; Robert Shafer; Maurizio Zazzi; Andrew Zolopa; Victor DeGruttola Journal: Antivir Ther Date: 2004-08
Authors: José Valdez Madruga; Daniel Berger; Marilyn McMurchie; Fredy Suter; Denes Banhegyi; Kiat Ruxrungtham; Dorece Norris; Eric Lefebvre; Marie-Pierre de Béthune; Frank Tomaka; Martine De Pauw; Tony Vangeneugden; Sabrina Spinosa-Guzman Journal: Lancet Date: 2007-07-07 Impact factor: 79.321
Authors: Gaetana Sterrantino; Mauro Zaccarelli; Antonio Di Biagio; Maria Luisa Biondi; Andrea Antinori; Giovanni Penco Journal: Infection Date: 2015-03-28 Impact factor: 3.553
Authors: Mina Henes; Klajdi Kosovrasti; Gordon J Lockbaum; Florian Leidner; Gily S Nachum; Ellen A Nalivaika; Daniel N A Bolon; Nese Kurt Yilmaz; Celia A Schiffer; Troy W Whitfield Journal: Biochemistry Date: 2019-08-19 Impact factor: 3.162
Authors: William J Allen; Trent E Balius; Sudipto Mukherjee; Scott R Brozell; Demetri T Moustakas; P Therese Lang; David A Case; Irwin D Kuntz; Robert C Rizzo Journal: J Comput Chem Date: 2015-06-05 Impact factor: 3.376
Authors: Arun K Ghosh; Zilei Xia; Satish Kovela; William L Robinson; Megan E Johnson; Daniel W Kneller; Yuan-Fang Wang; Manabu Aoki; Yuki Takamatsu; Irene T Weber; Hiroaki Mitsuya Journal: ChemMedChem Date: 2019-10-04 Impact factor: 3.466
Authors: Nathan E Goldfarb; Meray Ohanessian; Shyamasri Biswas; T Dwight McGee; Brian P Mahon; David A Ostrov; Jose Garcia; Yan Tang; Robert McKenna; Adrian Roitberg; Ben M Dunn Journal: Biochemistry Date: 2015-01-07 Impact factor: 3.162